Experimental use of combination therapy consisting of crizotinib and temozolomide to desensitize and target FIG-ROS1 fusions in cell cultures from adult GBM has had a profound antitumor effect in vitro and ex vivo (57). Here, ROS1 is linked to glioblastoma.